This $23,548,569.00 cost-plus-fixed-fee federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Crestone, Inc., a biotech company, to advance a small-molecule compound CRS0540 to investigational new drug filing and through Phase I clinical studies. The contract is not set aside. Crestone specializes in researching treatments for antibiotic-resistant bacterial infections and has received over $50 million in previous federal contracts and grants from NIAID and the Department of Veterans Affairs to support its work on novel therapies for Clostridioides difficile and other resistant infections. This contract appears to be related to a prior NIAID Broad Agency Announcement seeking proposals to develop medical countermeasures to mitigate and treat radiation injuries from a radiological or nuclear incident.
Generated 11/27/24, 9:28 AM